Home › Drugs A to Z › I › Is › Isradipine Pregnancy Warnings
Print Save or Share

Isradipine Pregnancy and Breastfeeding Warnings

Isradipine is also known as: DynaCirc CR, Dynacirc

Overview

If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Isradipine Extended-Release Tablets while you are pregnant. It is not known if Isradipine Extended-Release Tablets are found in breast milk. Do not breast-feed while taking Isradipine Extended-Release Tablets.

Isradipine Pregnancy Warnings

Isradipine has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of embryotoxicity at doses which were safe to the mother. There is no evidence of teratogenicity at any dose tested. Animal studies have revealed decreased maternal weight gain at doses up to 150 times the maximum recommended human dose (on a per kg basis), but there were no lasting effects on either the mother or offspring. A controlled study from human pregnancy is available that demonstrates isradipine may be used safely and efficaciously to treat pregnancy-induced hypertension without significantly affecting uterine blood flow. Isradipine should be given during pregnancy only when benefit outweighs risk.

Isradipine crosses the placental barrier, with a fetal to maternal plasma concentration ratio varying between 0.25 and 0.85. There are no known negative effects on neonatal outcome after isradipine 5 mg twice a day. At least 4 studies (2 using 0.3 mg IV, 1 using 5 mg PO BID, and on using 2.5 mg PO BID) have shown that isradipine can effectively and safely lower blood pressure without altering umbilical and uterine artery blood flow. Doses up to 1.5 mg IV to normotensive women has resulted in a 10% reduction in uterine contractility, significant hypotension in at least one case, and a mean increase in maternal heart rate by 20% to 30%. The various features of the fetal heart rate pattern, as evaluated in a controlled trial by computerized cardiotocography in human pregnancy, were not influenced by isradipine SR 5 mg twice a day in 23 women with preeclampsia. Because limited data have failed to show that the use of isradipine can effectively lower blood pressure in pregnant patients with hypertension and proteinuria, some experts believe that isradipine is not effective for the treatment of preeclampsia.

Isradipine Breastfeeding Warnings

There are no data on the excretion of isradipine into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

(web6)